The EPIsoDE Trial

A Clinical Study Testing Psilocybin for Treatment-Resistant Depression

The EPIsoDE Study is being conducted by the Central Institute of Mental Health (CIMH) in Mannheim, Germany (Principal Investigator: Prof. Dr. med. Gerhard Gründer). A second study center has been established at Charité Universitätsmedizin Berlin. The study is funded by the German Federal Ministry of Education and Research (BMBF). The MIND Foundation is an official study partner providing expertise, personnel, and additional funding.

The acronym “EPIsoDE” (Efficacy and safety of Psilocybin In treatment-reSistant majOr DEpression) summarizes the aim of the study: To investigate whether psilocybin administered under supportive conditions in a controlled, randomized, double-blind design is a safe and effective treatment for depression patients whose symptoms cannot be adequately reduced with antidepressants. Over the course of the study, 144 patients will be treated in Mannheim and Berlin. The rationale and study design are explained in detail in a recent article published in the scientific journal Neuroscience Applied.

The EPIsoDE Study’s official website provides further information (in German language), including directions for potential study participants and referring physicians.

Support psychedelic research and therapy

Support psychedelic research and make psychedelic-augmented therapy a reality.

All donations – big or small – make a difference!


Newsletter der MIND

Melden Sie sich für unseren Newsletter an und wir halten Sie über alles, was mit der MIND Foundation zu tun hat, auf dem Laufenden.